Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)
Roddie, Claire, Tholouli, Eleni, Shaughnessy, Paul, Jabbour, Elias, Logan, Aaron C., Hodby, Katharine, Mountjoy, Luke, Bloor, Adrian John Clifton, Irvine, David, Linch, David C., Orchard, Kim H., Wilson, William, Popova, Bilyana, Dias, Juliana, Agliardi, Giulia, Spanswick, Victoria, Lowe, Helen, Mitsikakou, Marina, Charalambous, Eftychia, Dawes, Joanna, Raymond, Meera, Hu, Yanqing, Brugger, Wolfram, Pule, Martin A., Park, Jae H., Peggs, Karl
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients
Sarma, Anita, Evans, Charlotte, Dalal, Surita, Webster, Nichola, Rawstron, Andy, Shingles, Jane, Newton, Darren, Cairns, David Allan, Glover, Paul, Grand, Thomas, Warren, Helen, Bell, Sue, Girvan, Sean, Greatorex, Natasha, Hockaday, Anna, Jackson, Sharon, Phillips, David, Stones, David, Allsup, David, Bloor, Adrian John Clifton, Varghese, Abraham Mullasseril, Munir, Talha, Hillmen, Peter
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial
Rawstron, Andy, Webster, Nichola, Dalal, Surita, de Tute, Ruth M, Bell, Sue, Cairns, David Allan, Girvan, Sean, Greatorex, Natasha, Hockaday, Anna, Jackson, Sharon, Phillips, David, Stones, David, Allsup, David, Bloor, Adrian John Clifton, Sarma, Anita, Varghese, Abraham Mullasseril, Munir, Talha, Hillmen, Peter
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact
Dalal, Surita, Sarma, Anita, Shingles, Jane, Glover, Paul, Warren, Helen, Grand, Thomas, Webster, Nichola, Rawstron, Andy, Newton, Darren, Bell, Sue, Cairns, David Allan, Girvan, Sean, Greatorex, Natasha, Hockaday, Anna, Jackson, Sharon, Phillips, David, Stones, David, Allsup, David, Bloor, Adrian John Clifton, Varghese, Abraham Mullasseril, Munir, Talha, Hillmen, Peter
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study
Hillmen, Peter, Cairns, David Allan, Bloor, Adrian John Clifton, Allsup, David, Cwynarski, Kate, Pettitt, Andrew, Paneesha, Shankaranarayana, Fox, Christopher P., Eyre, Toby A., Forconi, Francesco, Elmusharaf, Nagah, Kennedy, Ben, Gribben, John G., Pemberton, Nicholas, Sheehy, Oonagh, Preston, Gavin, Schuh, Anna, Howard, Dena, Hockaday, Anna, Jackson, Sharon, Greatorex, Natasha, Girvan, Sean, Bell, Sue, Brown, Julia, Webster, Nichola, Dalal, Surita, de Tute, Ruth M, Rawstron, Andrew, Patten, Piers EM, Munir, Talha
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article